VEGF at the neurovascular interface: Therapeutic implications for motor neuron disease

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1762, Issue 11-12, 2006, Pages 1109-1121

  Lambrechts, Diether ^a   Carmeliet, Peter ^a  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

ALS; Blood vessel; Motor neuron; Neurodegenerative; Therapeutic; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ANGIOGENIN; ANTISENSE OLIGONUCLEOTIDE; BRAIN DERIVED GROWTH FACTOR; CILIARY NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LEUKEMIA INHIBITORY FACTOR; NEUROPILIN; NEUROTROPHIC FACTOR; NEUROTROPIC AGENT; RECOMBINANT PROTEIN; RECOMBINANT VASCULOTROPIN; SOMATOMEDIN C; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ADENOVIRUS VECTOR; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BRAIN REGION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; COGNITION; COLORECTAL CANCER; DEGENERATIVE DISEASE; DISEASE EXACERBATION; DRUG SAFETY; DRUG TOLERABILITY; FEASIBILITY STUDY; GENE TRANSFER; HUMAN; IMMUNOREACTIVITY; INNATE IMMUNITY; LENTIVIRUS VECTOR; META ANALYSIS; MOTOR NEURON DISEASE; NERVE CELL DEGENERATION; NERVE CELL DIFFERENTIATION; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SPINAL CORD INJURY; SYSTEMATIC REVIEW; VIRAL GENE THERAPY;

AMYOTROPHIC LATERAL SCLEROSIS; ANGIOGENESIS INDUCING AGENTS; ANIMALS; CENTRAL NERVOUS SYSTEM; CHROMOSOMES, HUMAN, X; GENE THERAPY; HUMANS; IMMUNOPHILINS; LENTIVIRUS; MICE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; MOTOR NEURON DISEASE; MOTOR NEURONS; MUSCULAR ATROPHY, SPINAL; RIBONUCLEASE, PANCREATIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MUS MUSCULUS;

EID: 33751210105     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2006.04.005     Document Type: Review

References (134)

1. Carmeliet P., and Tessier-Lavigne M. Common mechanisms of nerve and blood vessel wiring. Nature 436 (2005) 193-200
2. Carmeliet P. Blood vessels and nerves: common signals, pathways and diseases. Nat. Rev., Genet. 4 (2003) 710-720
3. Breier G., Clauss M., and Risau W. Coordinate expression of vascular endothelial growth factor receptor-1 (flt-1) and its ligand suggests a paracrine regulation of murine vascular development. Dev. Dyn. 204 (1995) 228-239
4. Dumont D.J., Fong G.H., Puri M.C., Gradwohl G., Alitalo K., and Breitman M.L. Vascularization of the mouse embryo: a study of flk-1, tek, tie, and vascular endothelial growth factor expression during development. Dev. Dyn. 203 (1995) 80-92
5. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat. Med. 9 (2003) 669-676
6. Stalmans I., Ng Y.S., Rohan R., Fruttiger M., Bouche A., Yuce A., Fujisawa H., Hermans B., Shani M., Jansen S., Hicklin D., Anderson D.J., Gardiner T., Hammes H.P., Moons L., Dewerchin M., Collen D., Carmeliet P., and D'Amore P.A. Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J. Clin. Invest. 109 (2002) 327-336
7. Carmeliet P., Ferreira V., Breier G., Pollefeyt S., Kieckens L., Gertsenstein M., Fahrig M., Vandenhoeck A., Harpal K., Eberhardt C., Declercq C., Pawling J., Moons L., Collen D., Risau W., and Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380 (1996) 435-439
8. Ferrara N., Carver-Moore K., Chen H., Dowd M., Lu L., O'Shea K.S., Powell-Braxton L., Hillan K.J., and Moore M.W. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380 (1996) 439-442
9. Carmeliet P., Ng Y.S., Nuyens D., Theilmeier G., Brusselmans K., Cornelissen I., Ehler E., Kakkar V.V., Stalmans I., Mattot V., Perriard J.C., Dewerchin M., Flameng W., Nagy A., Lupu F., Moons L., Collen D., D'Amore P.A., and Shima D.T. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat. Med. 5 (1999) 495-502
10. Mattot V., Moons L., Lupu F., Chernavvsky D., Gomez R.A., Collen D., and Carmeliet P. Loss of the VEGF(164) and VEGF(188) isoforms impairs postnatal glomerular angiogenesis and renal arteriogenesis in mice. J. Am. Soc. Nephrol. 13 (2002) 1548-1560
11. Maes C., Carmeliet P., Moermans K., Stockmans I., Smets N., Collen D., Bouillon R., and Carmeliet G. Impaired angiogenesis and endochondral bone formation in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Mech. Dev. 111 (2002) 61-73
12. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 25 (2004) 581-611
13. Ferrara N., Hillan K.J., Gerber H.P., and Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev., Drug Discov. 3 (2004) 391-400
14. Breier G., Albrecht U., Sterrer S., and Risau W. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development 114 (1992) 521-532
15. Millauer B., Wizigmann-Voos S., Schnurch H., Martinez R., Moller N.P., Risau W., and Ullrich A. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72 (1993) 835-846
16. Ogunshola O.O., Stewart W.B., Mihalcik V., Solli T., Madri J.A., and Ment L.R. Neuronal VEGF expression correlates with angiogenesis in postnatal developing rat brain. Brain Res.. Dev. Brain Res.. 119 (2000) 139-153
17. Haigh J.J., Morelli P.I., Gerhardt H., Haigh K., Tsien J., Damert A., Miquerol L., Muhlner U., Klein R., Ferrara N., Wagner E.F., Betsholtz C., and Nagy A. Cortical and retinal defects caused by dosage-dependent reductions in VEGF-A paracrine signaling. Dev. Biol. 262 (2003) 225-241
18. Raab S., Beck H., Gaumann A., Yuce A., Gerber H.P., Plate K., Hammes H.P., Ferrara N., and Breier G. Impaired brain angiogenesis and neuronal apoptosis induced by conditional homozygous inactivation of vascular endothelial growth factor. Thromb. Haemost. 91 (2004) 595-605
19. Wang Y., Kilic E., Kilic U., Weber B., Bassetti C.L., Marti H.H., and Hermann D.M. VEGF overexpression induces post-ischaemic neuroprotection, but facilitates haemodynamic steal phenomena. Brain 128 (2005) 52-63
20. Ruhrberg C., Gerhardt H., Golding M., Watson R., Ioannidou S., Fujisawa H., Betsholtz C., and Shima D.T. Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes Dev. 16 (2002) 2684-2698
21. Mukouyama Y.S., Shin D., Britsch S., Taniguchi M., and Anderson D.J. Sensory nerves determine the pattern of arterial differentiation and blood vessel branching in the skin. Cell 109 (2002) 693-705
22. Bates D., Taylor G.I., Minichiello J., Farlie P., Cichowitz A., Watson N., Klagsbrun M., Mamluk R., and Newgreen D.F. Neurovascular congruence results from a shared patterning mechanism that utilizes semaphorin3A and neuropilin-1. Dev. Biol. 255 (2003) 77-98
23. Kutcher M.E., Klagsbrun M., and Mamluk R. VEGF is required for the maintenance of dorsal root ganglia blood vessels but not neurons during development. FASEB J. 18 (2004) 1952-1954
24. Mukouyama Y.S., Gerber H.P., Ferrara N., Gu C., and Anderson D.J. Peripheral nerve-derived VEGF promotes arterial differentiation via neuropilin 1-mediated positive feedback. Development 132 (2005) 941-952
25. Guttmann-Raviv N., Kessler O., Shraga-Heled N., Lange T., Herzog Y., and Neufeld G. The neuropilins and their role in tumorigenesis and tumor progression. Cancer Lett. 231 (2006) 1-11
26. Gu C., Limberg B.J., Whitaker G.B., Perman B., Leahy D.J., Rosenbaum J.S., Ginty D.D., and Kolodkin A.L. Characterization of neuropilin-1 structural features that confer binding to semaphorin 3A and vascular endothelial growth factor 165. J. Biol. Chem. 277 (2002) 18069-18076
27. Lee P., Goishi K., Davidson A.J., Mannix R., Zon L., and Klagsbrun M. Neuropilin-1 is required for vascular development and is a mediator of VEGF-dependent angiogenesis in zebrafish. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 10470-10475
28. Kitsukawa T., Shimizu M., Sanbo M., Hirata T., Taniguchi M., Bekku Y., Yagi T., and Fujisawa H. Neuropilin-semaphorin III/D-mediated chemorepulsive signals play a crucial role in peripheral nerve projection in mice. Neuron 19 (1997) 995-1005
29. Kolodkin A.L., Levengood D.V., Rowe E.G., Tai Y.T., Giger R.J., and Ginty D.D. Neuropilin is a semaphorin III receptor. Cell 90 (1997) 753-762
30. Giger R.J., Cloutier J.F., Sahay A., Prinjha R.K., Levengood D.V., Moore S.E., Pickering S., Simmons D., Rastan S., Walsh F.S., Kolodkin A.L., Ginty D.D., and Geppert M. Neuropilin-2 is required in vivo for selective axon guidance responses to secreted semaphorins. Neuron 25 (2000) 29-41
31. He Z., and Tessier-Lavigne M. Neuropilin is a receptor for the axonal chemorepellent semaphorin III. Cell 90 (1997) 739-751
32. Takahashi T., Fournier A., Nakamura F., Wang L.H., Murakami Y., Kalb R.G., Fujisawa H., and Strittmatter S.M. Plexin-neuropilin-1 complexes form functional semaphorin-3A receptors. Cell 99 (1999) 59-69
33. Takahashi T., and Strittmatter S.M. Plexina1 autoinhibition by the plexin sema domain. Neuron 29 (2001) 429-439
34. Kawasaki T., Kitsukawa T., Bekku Y., Matsuda Y., Sanbo M., Yagi T., and Fujisawa H. A requirement for neuropilin-1 in embryonic vessel formation. Development 126 (1999) 4895-4902
35. Gu C., Rodriguez E.R., Reimert D.V., Shu T., Fritzsch B., Richards L.J., Kolodkin A.L., and Ginty D.D. Neuropilin-1 conveys semaphorin and VEGF signaling during neural and cardiovascular development. Dev. Cell 5 (2003) 45-57
36. Schwarz Q., Gu C., Fujisawa H., Sabelko K., Gertsenstein M., Nagy A., Taniguchi M., Kolodkin A.L., Ginty D.D., Shima D.T., and Ruhrberg C. Vascular endothelial growth factor controls neuronal migration and cooperates with Sema3A to pattern distinct compartments of the facial nerve. Genes Dev. 18 (2004) 2822-2834
37. Feldner J., Becker T., Goishi K., Schweitzer J., Lee P., Schachner M., Klagsbrun M., and Becker C.G. Neuropilin-1a is involved in trunk motor axon outgrowth in embryonic zebrafish. Dev. Dyn. 234 (2005) 535-549
38. Popovici C., Isnardon D., Birnbaum D., and Roubin R. Caenorhabditis elegans receptors related to mammalian vascular endothelial growth factor receptors are expressed in neural cells. Neurosci. Lett. 329 (2002) 116-120
39. Duchek P., Somogyi K., Jekely G., Beccari S., and Rorth P. Guidance of cell migration by the Drosophila PDGF/VEGF receptor. Cell 107 (2001) 17-26
40. Cho N.K., Keyes L., Johnson E., Heller J., Ryner L., Karim F., and Krasnow M.A. Developmental control of blood cell migration by the Drosophila VEGF pathway. Cell 108 (2002) 865-876
41. Storkebaum E., Lambrechts D., and Carmeliet P. VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. BioEssays 26 (2004) 943-954
42. Greenberg D.A., and Jin K. VEGF and ALS: the luckiest growth factor?. Trends Mol. Med. 10 (2004) 1-3
43. Sun F.Y., and Guo X. Molecular and cellular mechanisms of neuroprotection by vascular endothelial growth factor. J. Neurosci. Res. 79 (2005) 180-184
44. Greenberg D.A., and Jin K. From angiogenesis to neuropathology. Nature 438 (2005) 954-959
45. Rosenstein J.M., Mani N., Khaibullina A., and Krum J.M. Neurotrophic effects of vascular endothelial growth factor on organotypic cortical explants and primary cortical neurons. J. Neurosci. 23 (2003) 11036-11044
46. Oosthuyse B., Moons L., Storkebaum E., Beck H., Nuyens D., Brusselmans K., Van Dorpe J., Hellings P., Gorselink M., Heymans S., Theilmeier G., Dewerchin M., Laudenbach V., Vermylen P., Raat H., Acker T., Vleminckx V., Van Den Bosch L., Cashman N., Fujisawa H., Drost M.R., Sciot R., Bruyninckx F., Hicklin D.J., Ince C., Gressens P., Lupu F., Plate K.H., Robberecht W., Herbert J.M., Collen D., and Carmeliet P. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat. Genet. 28 (2001) 131-138
47. Van Den Bosch L., Storkebaum E., Vleminckx V., Moons L., Vanopdenbosch L., Scheveneels W., Carmeliet P., and Robberecht W. Effects of vascular endothelial growth factor (VEGF) on motor neuron degeneration. Neurobiol. Dis. 17 (2004) 21-28
48. Shiote M., Nagano I., Ilieva H., Murakami T., Narai H., Ohta Y., Nagata T., Shoji M., and Abe K. Reduction of a vascular endothelial growth factor receptor, fetal liver kinase-1, by antisense oligonucleotides induces motor neuron death in rat spinal cord exposed to hypoxia. Neuroscience 132 (2005) 175-182
49. Silverman W.F., Krum J.M., Mani N., and Rosenstein J.M. Vascular, glial and neuronal effects of vascular endothelial growth factor in mesencephalic explant cultures. Neuroscience 90 (1999) 1529-1541
50. Krum J.M., Mani N., and Rosenstein J.M. Angiogenic and astroglial responses to vascular endothelial growth factor administration in adult rat brain. Neuroscience 110 (2002) 589-604
51. Mani N., Khaibullina A., Krum J.M., and Rosenstein J.M. Activation of receptor-mediated angiogenesis and signaling pathways after VEGF administration in fetal rat CNS explants. J. Cereb. Blood Flow Metab. 23 (2003) 1420-1429
52. Forstreuter F., Lucius R., and Mentlein R. Vascular endothelial growth factor induces chemotaxis and proliferation of microglial cells. J. Neuroimmunol. 132 (2002) 93-98
53. Sondell M., Lundborg G., and Kanje M. Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. J. Neurosci. 19 (1999) 5731-5740
54. Schratzberger P., Schratzberger G., Silver M., Curry C., Kearney M., Magner M., Alroy J., Adelman L.S., Weinberg D.H., Ropper A.H., and Isner J.M. Favorable effect of VEGF gene transfer on ischemic peripheral neuropathy. Nat. Med. 6 (2000) 405-413
55. Bagnard D., Vaillant C., Khuth S.T., Dufay N., Lohrum M., Puschel A.W., Belin M.F., Bolz J., and Thomasset N. Semaphorin 3A-vascular endothelial growth factor-165 balance mediates migration and apoptosis of neural progenitor cells by the recruitment of shared receptor. J. Neurosci. 21 (2001) 3332-3341
56. Schanzer A., Wachs F.P., Wilhelm D., Acker T., Cooper-Kuhn C., Beck H., Winkler J., Aigner L., Plate K.H., and Kuhn H.G. Direct stimulation of adult neural stem cells in vitro and neurogenesis in vivo by vascular endothelial growth factor. Brain Pathol. 14 (2004) 237-248
57. Cao L., Jiao X., Zuzga D.S., Liu Y., Fong D.M., Young D., and During M.J. VEGF links hippocampal activity with neurogenesis, learning and memory. Nat. Genet. 36 (2004) 827-835
58. Rowland L.P., and Shneider N.A. Amyotrophic lateral sclerosis. N. Engl. J.Med. 344 (2001) 1688-1700
59. Bendotti C., and Carri M.T. Lessons from models of SOD1-linked familial ALS. Trends Mol. Med. 10 (2004) 393-400
60. Brown Jr. R.H., and Robberecht W. Amyotrophic lateral sclerosis: pathogenesis. Semin. Neurol. 21 (2001) 131-139
61. Bruijn L.I., Miller T.M., and Cleveland D.W. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu. Rev. Neurosci. 27 (2004) 723-749
62. Shaw C.E., al-Chalabi A., and Leigh N. Progress in the pathogenesis of amyotrophic lateral sclerosis. Curr. Neurol. Neurosci. Rep. 1 (2001) 69-76
63. Majoor-Krakauer D., Willems P.J., and Hofman A. Genetic epidemiology of amyotrophic lateral sclerosis. Clin. Genet. 63 (2003) 83-101
64. Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O'Regan J.P., Deng H.X., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362 (1993) 59-62
65. Cleveland D.W. From Charcot to SOD1: mechanisms of selective motor neuron death in ALS. Neuron 24 (1999) 515-520
66. Howland D.S., Liu J., She Y., Goad B., Maragakis N.J., Kim B., Erickson J., Kulik J., DeVito L., Psaltis G., DeGennaro L.J., Cleveland D.W., and Rothstein J.D. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 1604-1609
67. Nagai M., Aoki M., Miyoshi I., Kato M., Pasinelli P., Kasai N., Brown Jr. R.H., and Itoyama Y. Rats expressing human cytosolic copper-zinc superoxide dismutase transgenes with amyotrophic lateral sclerosis: associated mutations develop motor neuron disease. J. Neurosci. 21 (2001) 9246-9254
68. Nishimura A.L., Mitne-Neto M., Silva H.C., Richieri-Costa A., Middleton S., Cascio D., Kok F., Oliveira J.R., Gillingwater T., Webb J., Skehel P., and Zatz M. A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am. J. Hum. Genet. 75 (2004) 822-831
69. Yang Y., Hentati A., Deng H.X., Dabbagh O., Sasaki T., Hirano M., Hung W.Y., Ouahchi K., Yan J., Azim A.C., Cole N., Gascon G., Yagmour A., Ben-Hamida M., Pericak-Vance M., Hentati F., and Siddique T. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat. Genet. 29 (2001) 160-165
70. Hand C.K., Devon R.S., Gros-Louis F., Rochefort D., Khoris J., Meininger V., Bouchard J.P., Camu W., Hayden M.R., and Rouleau G.A. Mutation screening of the ALS2 gene in sporadic and familial amyotrophic lateral sclerosis. Arch. Neurol. 60 (2003) 1768-1771
71. Chen Y.Z., Bennett C.L., Huynh H.M., Blair I.P., Puls I., Irobi J., Dierick I., Abel A., Kennerson M.L., Rabin B.A., Nicholson G.A., Auer-Grumbach M., Wagner K., De Jonghe P., Griffin J.W., Fischbeck K.H., Timmerman V., Cornblath D.R., and Chance P.F. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am. J. Hum. Genet. 74 (2004) 1128-1135
72. Lambrechts D., Storkebaum E., and Carmeliet P. VEGF: necessary to prevent motoneuron degeneration, sufficient to treat ALS?. Trends Mol. Med. 10 (2004) 275-282
73. Xie Y., Weydt P., Howland D.S., Kliot M., and Moller T. Inflammatory mediators and growth factors in the spinal cord of G93A SOD1 rats. NeuroReport 15 (2004) 2513-2516
74. Devos D., Moreau C., Lassalle P., Perez T., De Seze J., Brunaud-Danel V., Destee A., Tonnel A.B., and Just N. Low levels of the vascular endothelial growth factor in CSF from early ALS patients. Neurology 62 (2004) 2127-2129
75. Terry P.D., Kamel F., Umbach D.M., Lehman T.A., Hu H., Sandler D.P., and Taylor J.A. VEGF promoter haplotype and amyotrophic lateral sclerosis (ALS). J. Neurogenet. 18 (2004) 429-434
76. Van Vught P., Sutedja N., Veldink J., Koeleman B., Groeneveld G., Wijmenga C., UItdehaag B., De Jong J., Baas F., Wokke J., and Van den Berg L. Lack of association between VEGF polymorphisms and ALS in a Dutch population. Neurology 65 (2005) 1643-1645
77. Brockington A., Kirby J., Eggitt D., Schofield E., Morris C., Lewis C.E., Ince P.G., and Shaw P.J. Screening of the regulatory and coding regions of vascular endothelial growth factor in amyotrophic lateral sclerosis. Neurogenetics 6 (2005) 101-104
78. Lohmueller K.E., Pearce C.L., Pike M., Lander E.S., and Hirschhorn J.N. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat. Genet. 33 (2003) 177-182
79. Moreau C., Devos D., Brunaud-Danel V., Defebvre L., Perez T., Destee A., Tonnel A.B., Lassalle P., and Just N. Paradoxical response of VEGF expression to hypoxia in CSF of patients with ALS. J. Neurol. Neurosurg. Psychiatry 77 (2006) 255-257
80. Brockington A., Wharton S.B., Fernando M., Gelsthorpe C.H., Baxter L., Ince P.G., Lewis C.E., and Shaw P.J. Expression of vascular endothelial growth factor and its receptors in the central nervous system in amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 65 (2006) 26-36
81. Storkebaum E., Lambrechts D., Dewerchin M., Moreno-Murciano M.P., Appelmans S., Oh H., Van Damme P., Rutten B., Man W.Y., De Mol M., Wyns S., Manka D., Vermeulen K., Van Den Bosch L., Mertens N., Schmitz C., Robberecht W., Conway E.M., Collen D., Moons L., and Carmeliet P. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat. Neurosci. 8 (2005) 85-92
82. Sopher B.L., Thomas Jr. P.S., LaFevre-Bernt M.A., Holm I.E., Wilke S.A., Ware C.B., Jin L.W., Libby R.T., Ellerby L.M., and La Spada A.R. Androgen receptor YAC transgenic mice recapitulate SBMA motor neuronopathy and implicate VEGF164 in the motor neuron degeneration. Neuron 41 (2004) 687-699
83. Greenway M.J., Alexander M.D., Ennis S., Traynor B.J., Corr B., Frost E., Green A., and Hardiman O. A novel candidate region for ALS on chromosome 14q11.2. Neurology 63 (2004) 1936-1938
84. Greenway M.J., Andersen P.M., Russ C., Ennis S., Cashman S., Donaghy C., Patterson V., Swingler R., Kieran D., Prehn J., Morrison K.E., Green A., Acharya K.R., Brown R.H., and Hardiman O. ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis. Nat. Genet. 38 (2006) 411-413
85. Adams S.A., and Subramanian V. The angiogenins: an emerging family ofribonuclease related proteins with diverse cellular functions. Angiogenesis 3 (1999) 189-199
86. Kishimoto K., Liu S., Tsuji T., Olson K.A., and Hu G.F. Endogenous angiogenin in endothelial cells is a general requirement for cell proliferation and angiogenesis. Oncogene 24 (2005) 445-456
87. Hooper L.V., Stappenbeck T.S., Hong C.V., and Gordon J.I. Angiogenins: a new class of microbicidal proteins involved in innate immunity. Nat. Immunol. 4 (2003) 269-273
88. Tsuji T., Sun Y., Kishimoto K., Olson K.A., Liu S., Hirukawa S., and Hu G.F. Angiogenin is translocated to the nucleus of HeLa cells and is involved in ribosomal RNA transcription and cell proliferation. Cancer Res. 65 (2005) 1352-1360
89. Bensimon G., Lacomblez L., and Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N. Engl. J.Med. 330 (1994) 585-591
90. Mitsumoto H., Gordon P., Kaufmann P., Gooch C.L., Przedborski S., and Rowland L.P. Randomized control trials in ALS: lessons learned. Amyotroph. Lateral Scler. Other Mot. Neuron Disord. 5 Suppl 1 (2004) 8-13
91. Thoenen H., and Sendtner M. Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches. Nat. Neurosci. 5 (2002) 1046-1050 (Suppl)
92. Aebischer P., and Ridet J. Recombinant proteins for neurodegenerative diseases: the delivery issue. Trends Neurosci. 24 (2001) 533-540
93. Borasio G.D., Robberecht W., Leigh P.N., Emile J., Guiloff R.J., Jerusalem F., Silani V., Vos P.E., Wokke J.H., and Dobbins T. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology 51 (1998) 583-586
94. Lai E.C., Felice K.J., Festoff B.W., Gawel M.J., Gelinas D.F., Kratz R., Murphy M.F., Natter H.M., Norris F.H., and Rudnicki S.A. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group. Neurology 49 (1997) 1621-1630
95. Feeney S.J., Austin L., Bennett T.M., Kurek J.B., Jean-Francois M.J., Muldoon C., and Byrne E. The effect of leukaemia inhibitory factor on SOD1 G93A murine amyotrophic lateral sclerosis. Cytokine 23 (2003) 108-118
96. Azari M.F., Lopes E.C., Stubna C., Turner B.J., Zang D., Nicola N.A., Kurek J.B., and Cheema S.S. Behavioural and anatomical effects of systemically administered leukemia inhibitory factor in the SOD1(G93A G1H) mouse model of familial amyotrophic lateral sclerosis. Brain Res. 982 (2003) 92-97
97. Thorne R.G., and Frey II W.H. Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin. Pharmacokinet. 40 (2001) 907-946
98. Kaspar B.K., Llado J., Sherkat N., Rothstein J.D., and Gage F.H. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301 (2003) 839-842
99. Azzouz M., Ralph G.S., Storkebaum E., Walmsley L.E., Mitrophanous K.A., Kingsman S.M., Carmeliet P., and Mazarakis N.D. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 429 (2004) 413-417
100. Mazarakis N.D., Azzouz M., Rohll J.B., Ellard F.M., Wilkes F.J., Olsen A.L., Carter E.E., Barber R.D., Baban D.F., Kingsman S.M., Kingsman A.J., O'Malley K., and Mitrophanous K.A. Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. Hum. Mol. Genet. 10 (2001) 2109-2121
101. Charlton K.M. The pathogenesis of rabies and other lyssaviral infections: recent studies. Curr. Top. Microbiol. Immunol. 187 (1994) 95-119
102. M. Azzouz, Gene therapy for ALS: progress and prospects, Biochim. Biophys. Acta (in press). doi:10.1016/j.bbadis.2006.05.003.
103. Zheng C., Nennesmo I., Fadeel B., and Henter J.I. Vascular endothelial growth factor prolongs survival in a transgenic mouse model of ALS. Ann. Neurol. 56 (2004) 564-567
104. Chi O.Z., Hunter C., Liu X., and Weiss H.R. Effects of VEGF and nitric oxide synthase inhibition on blood-brain barrier disruption in the ischemic and non-ischemic cerebral cortex. Neurol. Res. 27 (2005) 864-868
105. Valable S., Montaner J., Bellail A., Berezowski V., Brillault J., Cecchelli R., Divoux D., Mackenzie E.T., Bernaudin M., Roussel S., and Petit E. VEGF-induced BBB permeability is associated with an MMP-9 activity increase in cerebral ischemia: both effects decreased by Ang-1. J. Cereb. Blood Flow Metab. 25 (2005) 1491-1504
106. Zhang Z.G., Zhang L., Jiang Q., Zhang R., Davies K., Powers C., Bruggen N., and Chopp M. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J. Clin. Invest. 106 (2000) 829-838
107. van Bruggen N., Thibodeaux H., Palmer J.T., Lee W.P., Fu L., Cairns B., Tumas D., Gerlai R., Williams S.P., van Lookeren Campagne M., and Ferrara N. VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain. J. Clin. Invest. 104 (1999) 1613-1620
108. Benton R.L., and Whittemore S.R. VEGF165 therapy exacerbates secondary damage following spinal cord injury. Neurochem. Res. 28 (2003) 1693-1703
109. Kovacs Z., Ikezaki K., Samoto K., Inamura T., and Fukui M. VEGF and flt. Expression time kinetics in rat brain infarct. Stroke 27 (1996) 1865-1872 (discussion 1872-1873)
110. Hayashi T., Abe K., Suzuki H., and Itoyama Y. Rapid induction of vascular endothelial growth factor gene expression after transient middle cerebral artery occlusion in rats. Stroke 28 (1997) 2039-2044
111. Lennmyr F., Ata K.A., Funa K., Olsson Y., and Terent A. Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) following permanent and transient occlusion of the middle cerebral artery in the rat. J. Neuropathol. Exp. Neurol. 57 (1998) 874-882
112. Plate K.H., Beck H., Danner S., Allegrini P.R., and Wiessner C. Cell type specific upregulation of vascular endothelial growth factor in an MCA-occlusion model of cerebral infarct. J. Neuropathol. Exp. Neurol. 58 (1999) 654-666
113. Sun Y., Jin K., Xie L., Childs J., Mao X.O., Logvinova A., and Greenberg D.A. VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J. Clin. Invest. 111 (2003) 1843-1851
114. Yano A., Shingo T., Takeuchi A., Yasuhara T., Kobayashi K., Takahashi K., Muraoka K., Matsui T., Miyoshi Y., Hamada H., and Date I. Encapsulated vascular endothelial growth factor-secreting cell grafts have neuroprotective and angiogenic effects on focal cerebral ischemia. J. Neurosurg. 103 (2005) 104-114
115. Lambrechts D., Storkebaum E., Morimoto M., Del-Favero J., Desmet F., Marklund S.L., Wyns S., Thijs V., Andersson J., van Marion I., Al-Chalabi A., Bornes S., Musson R., Hansen V., Beckman L., Adolfsson R., Pall H.S., Prats H., Vermeire S., Rutgeerts P., Katayama S., Awata T., Leigh N., Lang-Lazdunski L., Dewerchin M., Shaw C., Moons L., Vlietinck R., Morrison K.E., Robberecht W., Van Broeckhoven C., Collen D., Andersen P.M., and Carmeliet P. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat. Genet. 34 (2003) 383-394
116. Widenfalk J., Lipson A., Jubran M., Hofstetter C., Ebendal T., Cao Y., and Olson L. Vascular endothelial growth factor improves functional outcome and decreases secondary degeneration in experimental spinal cord contusion injury. Neuroscience 120 (2003) 951-960
117. Sun Y., Jin K., Childs J.T., Xie L., Mao X.O., and Greenberg D.A. Increased severity of cerebral ischemic injury in vascular endothelial growth factor-B-deficient mice. J. Cereb. Blood Flow Metab. 24 (2004) 1146-1152
118. Sun Y., Jin K., Childs J.T., Xie L., Mao X.O., and Greenberg D.A. Vascular endothelial growth factor-B (VEGFB) stimulates neurogenesis: evidence from knockout mice and growth factor administration. Dev. Biol. 289 (2005) 329-335
119. Croll S.D., Goodman J.H., and Scharfman H.E. Vascular endothelial growth factor (VEGF) in seizures: a double-edged sword. Adv. Exp. Med. Biol. 548 (2004) 57-68
120. Matsuzaki H., Tamatani M., Yamaguchi A., Namikawa K., Kiyama H., Vitek M.P., Mitsuda N., and Tohyama M. Vascular endothelial growth factor rescues hippocampal neurons from glutamate-induced toxicity: signal transduction cascades. FASEB J. 15 (2001) 1218-1220
121. McCloskey D.P., Croll S.D., and Scharfman H.E. Depression of synaptic transmission by vascular endothelial growth factor in adult rat hippocampus and evidence for increased efficacy after chronic seizures. J. Neurosci. 25 (2005) 8889-8897
122. Schratzberger P., Walter D.H., Rittig K., Bahlmann F.H., Pola R., Curry C., Silver M., Krainin J.G., Weinberg D.H., Ropper A.H., and Isner J.M. Reversal of experimental diabetic neuropathy by VEGF gene transfer. J. Clin. Invest. 107 (2001) 1083-1092
123. Chattopadhyay M., Krisky D., Wolfe D., Glorioso J.C., Mata M., and Fink D.J. HSV-mediated gene transfer of vascular endothelial growth factor to dorsal root ganglia prevents diabetic neuropathy. Gene Ther. (2005)
124. Hobson M.I., Green C.J., and Terenghi G. VEGF enhances intraneural angiogenesis and improves nerve regeneration after axotomy. J.Anat. 197 Pt 4 (2000) 591-605
125. Kalaria R.N. Small vessel disease and Alzheimer's dementia: pathological considerations. Cerebrovasc. Dis. 13 Suppl 2 (2002) 48-52
126. Yang S.P., Bae D.G., Kang H.J., Gwag B.J., Gho Y.S., and Chae C.B. Co-accumulation of vascular endothelial growth factor with beta-amyloid in the brain of patients with Alzheimer's disease. Neurobiol. Aging 25 (2004) 283-290
127. Thal D.R., Ghebremedhin E., Orantes M., and Wiestler O.D. Vascular pathology in Alzheimer disease: correlation of cerebral amyloid angiopathy and arteriosclerosis/lipohyalinosis with cognitive decline. J. Neuropathol. Exp. Neurol. 62 (2003) 1287-1301
128. Del Bo R., Scarlato M., Ghezzi S., Martinelli Boneschi F., Fenoglio C., Galbiati S., Virgilio R., Galimberti D., Galimberti G., Crimi M., Ferrarese C., Scarpini E., Bresolin N., and Comi G.P. Vascular endothelial growth factor gene variability is associated with increased risk for AD. Ann. Neurol. 57 (2005) 373-380
129. Chapuis J., Tian J., Shi J., Bensemain F., Cottel D., Lendon C., Amouyel P., Mann D., and Lambert J.C. Association study of the vascular endothelial growth factor gene with the risk of developing Alzheimer's disease. Neurobiol. Aging (2005)
130. Tarkowski E., Issa R., Sjogren M., Wallin A., Blennow K., Tarkowski A., and Kumar P. Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia. Neurobiol. Aging 23 (2002) 237-243
131. Kalaria R.N., Cohen D.L., Premkumar D.R., Nag S., LaManna J.C., and Lust W.D. Vascular endothelial growth factor in Alzheimer's disease and experimental cerebral ischemia. Brain Res. Mol Brain Res. 62 (1998) 101-105
132. Yasuhara T., Shingo T., Muraoka K., Kameda M., Agari T., Wen Ji Y., Hayase H., Hamada H., Borlongan C.V., and Date I. Neurorescue effects of VEGF on a rat model of Parkinson's disease. Brain Res. 1053 (2005) 10-18
133. Yasuhara T., Shingo T., Muraoka K., wen Ji Y., Kameda M., Takeuchi A., Yano A., Nishio S., Matsui T., Miyoshi Y., Hamada H., and Date I. The differences between high and low-dose administration of VEGF to dopaminergic neurons of in vitro and in vivo Parkinson's disease model. Brain Res. 1038 (2005) 1-10
134. Pitzer M.R., Sortwell C.E., Daley B.F., McGuire S.O., Marchionini D., Fleming M., and Collier T.J. Angiogenic and neurotrophic effects of vascular endothelial growth factor (VEGF165): studies of grafted and cultured embryonic ventral mesencephalic cells. Exp. Neurol. 182 (2003) 435-445